利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.025 秒)

    Deuterated pyrazinoisoquinoline compounds
    1.
    发明授权
    Deuterated pyrazinoisoquinoline compounds 有权
    氘化吡嗪异喹啉化合物

    公开(公告)号：US08889687B2

    公开(公告)日：2014-11-18

    申请号：US13411198

    申请日：2012-03-02

    申请人： Julie F. Liu ,  Roger Tung ,  Scott L. Harbeson

    发明人： Julie F. Liu ,  Roger Tung ,  Scott L. Harbeson

    IPC分类号： A61K31/4985 ,  C07D471/04 ,  C07B59/00

    CPC分类号： C07D471/04 ,  A61K31/4184 ,  A61K31/4985 ,  C07B59/002 ,  Y02A50/411 ,  Y02A50/423

    摘要： This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译： 本发明在一个实施方案中涉及式Ia化合物; 其中指定（R）表示指定的碳具有（R）立体化学; 并且其中Z1是氢或氟; Z2是氢，氘或氟; Z3是氘; Z4是氟; m为0〜10的整数; n为0〜2的整数; 条件是：m + n的和不超过10; 并且当Z1和Z2均为氢时，m + n的和大于0，以及其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物，以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Deuterated pyrazinoisoquinoline compounds
    2.
    发明授权
    Deuterated pyrazinoisoquinoline compounds 有权
    氘化吡嗪异喹啉化合物

    公开(公告)号：US08563554B2

    公开(公告)日：2013-10-22

    申请号：US13256787

    申请日：2010-03-16

    申请人： Julie F. Liu ,  Scott L. Harbeson ,  Roger Tung

    发明人： Julie F. Liu ,  Scott L. Harbeson ,  Roger Tung

    IPC分类号： A61K31/495

    CPC分类号： C07D471/04 ,  A61K31/4184 ,  A61K31/4985 ,  A61K45/06 ,  Y02A50/411 ,  Y02A50/423 ,  A61K2300/00

    摘要： This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel, such as compounds of formula (I): or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译： 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地，本发明涉及作为吡喹酮的衍生物的新的吡嗪并喹啉衍生物，例如式（I）的化合物或其药学上可接受的盐。 本发明还提供包含一种或多种本发明化合物和载体的组合物，以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Fluorinated diaryl urea derivatives
    5.
    发明授权
    Fluorinated diaryl urea derivatives 有权
    氟化二芳基脲衍生物

    公开(公告)号：US08410082B2

    公开(公告)日：2013-04-02

    申请号：US13320646

    申请日：2010-05-20

    申请人： Julie F. Liu ,  Roger D. Tung ,  Scott L. Harbeson

    发明人： Julie F. Liu ,  Roger D. Tung ,  Scott L. Harbeson

    IPC分类号： A61K31/56 ,  A61K31/44 ,  A61K38/21 ,  A61K39/00 ,  A61K33/24 ,  C07D213/78

    CPC分类号： C07D213/81 ,  C07B59/002

    摘要： This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.

    摘要翻译： 本发明涉及新的二芳基脲化合物，其衍生物及其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用多种激酶抑制剂有益治疗的疾病和病症的方法中的用途。

    PYRAZINOISOQUINOLINE COMPOUNDS
    7.
    发明申请
    PYRAZINOISOQUINOLINE COMPOUNDS 有权
    吡咯烷酮化合物

    公开(公告)号：US20120149709A1

    公开(公告)日：2012-06-14

    申请号：US13256787

    申请日：2010-03-16

    申请人： Julie F. Liu ,  Roger Tung ,  Scott L. Harbeson

    发明人： Julie F. Liu ,  Roger Tung ,  Scott L. Harbeson

    IPC分类号： A61K31/498 ,  A01N43/90 ,  A01P15/00 ,  A61P33/12 ,  A61P33/10 ,  C07D471/04 ,  A61P33/06

    CPC分类号： C07D471/04 ,  A61K31/4184 ,  A61K31/4985 ,  A61K45/06 ,  Y02A50/411 ,  Y02A50/423 ,  A61K2300/00

    摘要： This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.

    摘要翻译： 本发明涉及吡嗪并异喹啉衍生物的新化合物及其药学上可接受的盐。 更具体地，本发明涉及作为吡喹酮衍生物的新型吡嗪异喹啉衍生物。 本发明还提供包含一种或多种本发明化合物和载体的组合物，以及所述化合物和组合物在治疗通过施用抗栓剂如吡喹酮有益治疗的疾病和病症的方法中的用途。

    Deuterium-substituted xanthine derivatives and methods of use
    8.
    发明授权
    Deuterium-substituted xanthine derivatives and methods of use 有权
    氘取代黄嘌呤衍生物及其使用方法

    公开(公告)号：US08987442B2

    公开(公告)日：2015-03-24

    申请号：US13448930

    申请日：2012-04-17

    申请人： Roger D. Tung ,  Julie F. Liu ,  Scott L. Harbeson

    发明人： Roger D. Tung ,  Julie F. Liu ,  Scott L. Harbeson

    IPC分类号： A61K31/522 ,  A61P13/12 ,  A61P43/00 ,  C07D473/06

    CPC分类号： A61K31/522 ,  C07D473/06

    摘要： This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

    摘要翻译： 本发明涉及作为取代黄嘌呤衍生物的新化合物及其药学上可接受的盐。 例如，本发明涉及作为己酮可可碱衍生物的新型取代黄嘌呤衍生物。 本发明还提供了包含一种或多种本发明化合物和载体的组合物，以及所述化合物和组合物在治疗己酮可可碱和相关化合物有益的疾病和病症的方法中的用途。

    Analogues of cilostazol
    10.
    发明授权
    Analogues of cilostazol 有权
    西洛他唑类似物

    公开(公告)号：US08349817B2

    公开(公告)日：2013-01-08

    申请号：US12644758

    申请日：2009-12-22

    申请人： Rose A. Persichetti ,  Julie F. Liu ,  Craig E. Masse ,  Scott L. Harbeson

    发明人： Rose A. Persichetti ,  Julie F. Liu ,  Craig E. Masse ,  Scott L. Harbeson

    IPC分类号： A61K31/4709 ,  A61K31/4365 ,  A61K31/616 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P11/06 ,  A61P29/00 ,  C07D401/12

    CPC分类号： C07D215/20 ,  A61K31/10 ,  A61K31/4365 ,  A61K31/4709 ,  A61K31/60 ,  C07D401/12

    摘要： This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.

    摘要翻译： 本发明涉及作为磷酸二酯酶抑制剂西洛他唑及其药学上可接受的盐的衍生物的新化合物。 本发明还提供了包含一种或多种本发明化合物的无热原组合物，以及所公开的化合物和组合物在治疗通过施用磷酸二酯酶抑制剂如西洛他唑治疗的疾病和病症的方法中的用途。 本发明还涉及所公开的化合物和组合物在涉及西洛他唑的分析研究中作为试剂的用途。